EU Health Claims Rules: What a Supplement Label Can Actually Say

A brand owner who has spent months on formulation naturally wants the label to say what the product does. In the EU, that instinct runs straight into a limit: only a defined set of wording is permitted against a given ingredient, and the fact that an active ingredient is genuinely present does not automatically license any wording a marketing team is happy with. The distance between an ingredient being present and a specific sentence being allowed on the label is where most first-time brand owners get caught out.

This is not a reason to avoid the category. It is a reason to separate two decisions that often get made together by accident: the formulation decision, which is yours and your manufacturer's to work through, and the claims-wording decision, which belongs to you and a regulatory advisor, informed by what is actually permitted for that ingredient in that market.

This is also why the claims conversation belongs earlier than most brand owners place it. Waiting until the label is designed to ask what wording is allowed turns a planning question into a rescue mission, usually right when a launch date is already being communicated to a retailer or a customer list.

Bring this question to your manufacturer at the same meeting where you discuss format and packaging, not as a follow-up email. A brief that already states which claims you intend to use lets everyone plan artwork, print and label review against the same target from day one.

The EU works from a shared list of claim wording that has already been through an assessment process; if a form of words is on that list for a given ingredient, it can generally be used, usually under conditions tied to how much of the ingredient the product actually contains. If a claim is not on the list, or sits in a category still working through assessment, using it anyway is a decision the brand owner is making alone, without the backing an approved claim provides.

None of this is about how well a product performs. It is about which sentences are allowed to describe that performance in a given market. A brand can be entirely confident in its formulation and still be barred from using a specific phrase to describe it, simply because that exact wording has not cleared the process.

It helps to think of the permitted list as a menu rather than a starting point for negotiation. A brand can choose from what is available for a given ingredient and build a marketing story around that choice, but cannot commission a new item on the menu simply because the existing wording undersells the formulation work that went into the product.

Brand owners sometimes assume that a close paraphrase of a permitted claim is as good as the claim itself. It usually is not. A permitted form of words is permitted as written, and a confident rewrite, punchier, more on-brand, more in line with a wider marketing campaign, can drift outside what was actually assessed, even when the underlying meaning feels identical to the person writing it.

The same caution applies to combining two permitted claims into one sentence, or attaching a permitted claim to an ingredient at a level the assessment did not cover. Both feel like small edits. Both can turn a defensible label into one that is not.

A related trap is assuming that a claim permitted for one ingredient automatically extends to a similar ingredient in the same category. Two botanicals, or two forms of the same vitamin, can sit in very different positions on the permitted list, and treating them as interchangeable at the label-writing stage is exactly the kind of shortcut that gets caught in a later review.

When in doubt about whether a rewrite has drifted from the approved wording, default to the wording as assessed rather than the version that reads well in a deck. A regulatory advisor can usually tell you quickly whether a specific phrase is still inside the approved form; guessing is the more expensive option.

Explicit wording is not the only place a claim can live. Packaging imagery, a product name, a before-and-after implication, or even a category placement can carry a claim without a single sentence stating it outright. A brand owner reviewing only the printed copy paragraph by paragraph can still end up shipping a label that reads, as a whole, as a claim nobody reviewed in writing.

This is part of why this programme's own product and ingredient copy avoids outcome-based marketing language and testimonials: an implied promise is still a promise, and responsibility for that promise sits with the brand owner regardless of where on the pack it appears.

The steadier test for a brand owner reviewing their own artwork is to ask what a reasonable shopper would take away from the pack as a whole, not just from the words in the ingredient panel. If the overall impression promises an outcome that the approved wording alone does not support, the label is carrying more of a claim than the brand intended to make.

A contract manufacturer can format, typeset and print exactly the wording a brand owner approves, and can flag when requested phrasing looks unusual against what is normally seen on comparable labels. What a manufacturer does not do is approve a claim's legal standing, draft new claims on a brand's behalf, or take on the compliance risk of wording written in-house or by a marketing agency.

That division exists because the manufacturer produces the physical product, not the legal basis of the sentences printed on it. Compliance ownership for label claims sits with the brand owner in every market the product reaches, which is also why a regulatory advisor belongs in the same conversation as your artwork designer, not a later one.

This also shapes what a reasonable brief to your manufacturer looks like: bring your regulatory advisor's confirmed wording, not a working draft you hope will be fine, to the artwork stage. A manufacturer producing to a locked, approved file is a much smoother process than one working against wording that is still being negotiated with a regulatory advisor in parallel.

This is also why claims wording, unlike formulation, is not something a manufacturer can price or plan around on your behalf. Your manufacturer needs a final file to print correctly; it is the brand owner's advisor who confirms that file says what it is legally allowed to say.

Brand owners who avoid reprint costs treat claims wording as a gate the label must pass through before it is locked, not a detail to check once everything else is finished. That means finalising which ingredient claims you intend to use, confirming with a regulatory advisor that the wording matches what is actually permitted, and only then handing the file to production.

Reversing that order, designing the label, then asking whether the wording is allowed, is how brand owners end up choosing between a delayed launch and a compromised label. Neither is a position worth negotiating from at the last stage of a production run.

Build this sequence into your project timeline the same way you would build in artwork proofing or packaging decisions: claims confirmation is a step, not a background assumption. A brand owner who treats it as a formal stage in the process rarely ends up needing an emergency reprint.

Even a carefully reviewed label can need a wording change later, an assessment outcome shifts, a market's interpretation tightens, or your own advisor flags something on a routine review. When that happens, the practical question is always the same: how much of your current stock and artwork is affected, and how quickly can a revised file move through production.

Planning for this possibility from the start, keeping artwork files organised, keeping your regulatory advisor in the loop as your range grows, turns an occasional wording correction into a manageable update instead of a scramble across every SKU in a range.

This is also a reason to avoid over-committing a large opening print run before a range's claims wording has settled across every market you plan to sell into. A smaller first run, reviewed and confirmed, is easier to correct than a large run that needs pulling from multiple markets at once.

Brand owners who keep a simple change log, what changed, when, and why, find these updates far less disruptive than those who treat every label as a one-off design project with no history to refer back to.

None of this replaces a conversation with a qualified regulatory advisor about your specific ingredients and specific markets; that advice is always market- and product-specific, and it is not something a manufacturer can substitute for. What a manufacturer can do is make sure the physical product and the approved wording arrive in the same file, ready for your review, every time.

If you are approaching a label review with a formula already in hand, bring your confirmed wording into your project brief so the production side of the conversation and the compliance side move together rather than in sequence.

None of this is a reason to under-sell a genuinely strong formulation. It is a reason to make sure the words describing that formulation have been through the same rigour as the formulation itself, so the label and the product are making the same promise, in a way that holds up under review.